Amgen Czech Republic's net debt reached CZK -0.283 mil and accounted for -0.147% of equity at the end of 2017. The ratio is down 17.4% when compared to the previous year.
Historically, the firm’s net debt to equity reached an all time high of 38.7% in 2015 and an all time low of -80.1% in 2005.
When compared to EBITDA, net debt amounted to -0.006x at the end of the year. The ratio reached an all time high of 1.53 in 2015 and an all time low of -2.63 in 2008.
|Amgen Czech Republic||...||...||-0.005||0.709||1.53|
|Bayer Czech Republic||-0.298||-0.098||0.140||0.150||0.890|
|GlaxoSmithKline Czech Republic||0.438||1.02||1.69||-0.001||-3.71|
|Merck Czech Republic||1.87||1.39||2.80||0.353||-0.026|
|Novartis Czech Republic||3.22||0.696||-0.064||0.826||-0.015|
|Pfizer Czech Republic||2.16||-1.32||-0.141||-1.65||-0.037|
|Roche Czech Republic||-0.002||0.737||0.867||2.04||3.15||...|
|Sanofi-Aventis Czech Republic||12.8||16.5||8.87||27.7||4.27|
|Servier Czech Republic||...||...||-1.54||-2.09||-1.74||-0.839|